Related Experiment Videos
[Segawa disease]
1Segawa Neurological Clinic for Children.
Rinsho Shinkeigaku = Clinical Neurology
|May 13, 1998
Summary
Segawa disease, a hereditary dystonia, is caused by GTP cyclohydrolase I (GCH-I) deficiency, leading to reduced dopamine. L-Dopa treatment is effective for this basal ganglia disorder.
Area of Science:
- Neurogenetics
- Biochemistry
- Movement Disorders
Context:
- Segawa disease, or hereditary progressive dystonia with marked diurnal fluctuation, is the first identified hereditary basal ganglia disorder with known genetic and enzymatic causes.
- It typically presents in childhood with unilateral foot dystonia that fluctuates throughout the day.
Purpose:
- To elucidate the genetic and biochemical underpinnings of Segawa disease.
- To understand the mechanism linking enzyme deficiency to specific neurological symptoms and diurnal fluctuations.
Summary:
- Deficiency in GTP cyclohydrolase I (GCH-I) leads to reduced tetrahydrobiopterin (BH4), subsequently decreasing tyrosine hydroxylase (TH) and dopamine (DA) in the nigrostriatal pathway.
- This biochemical deficit selectively impacts the D1-direct pathway, causing postural dystonia, while sparing other motor pathways.
- Diurnal symptom fluctuation is attributed to daily variations in TH and DA levels at the nigrostriatal terminal.
Impact:
- Identifies GCH-I deficiency and mutations as the primary etiology of Segawa disease.
- Explains the therapeutic efficacy of L-Dopa by addressing the dopamine deficit.
- Provides a framework for understanding other dopa-responsive dystonias and parkinsonian syndromes linked to pteridine metabolism.